Call Us Now

+91 9606900005 / 04

For Enquiry

legacyiasacademy@gmail.com

Costly HPV Vaccine Needs To Be Part of National Immunisation Programme

Overview

  • Cervical cancer, caused by the Human Papillomavirus (HPV), is among the leading causes of cancer in Indian women.
  • HPV is responsible for 99.7% of cervical cancers globally.
  • The HPV vaccine is highly effective, preventing over 90% of HPV-related cancers.

Relevance : GS 2(Health , Governance)

Current Situation in India

  • The HPV vaccine is available only via private practitioners, though NTAGI has recommended its inclusion in the national immunisation programme.
  • Some states, such as Punjab and Sikkim, have incorporated the vaccine into their immunisation schedules.
  • Recommended: Routine vaccination for girls at 9 years and a catch-up for those aged 9–14.

Benefits of the HPV Vaccine

  • Prevents cervical, vaginal, vulvar, anal, penile, and throat cancers caused by HPV.
  • Effective for both genders, offering protection against genital warts and HPV-related cancers.
  • Safe for immunocompromised individuals, including those with HIV.
  • Vaccines approved in India:
    • Gardasil: Quadrivalent (HPV-6, 11, 16, 18)
    • Cervarix: Bivalent
    • Cervavac: India-made, targets HPV-16 and 18.

Statistics on Cervical Cancer in India

  • 3rd most common cancer among women.
  • Accounts for 18.3% of all cancer cases and 9.1% of cancer deaths in women (GLOBOCAN 2020).
  • High prevalence in areas like Arunachal Pradesh (Papumpare district).

Challenges

  • Cost:
    • Gardasil 9: ₹10,850/dose.
    • Gardasil 4: ₹2,000–₹4,000/dose.
    • Cervavac: ₹2,000/dose.
  • Awareness: Limited understanding of its importance.
  • Cultural Factors: Stigma around reproductive health impacts acceptance.

Recommendations

  • Universal inclusion of the HPV vaccine in the national immunisation programme.
  • Promote awareness campaigns to address cultural and knowledge gaps.
  • Encourage vaccination for all genders to broaden HPV prevention.
  • Focus on vaccinating individuals before exposure (ideally 926 years).

Call to Action

The inclusion of the HPV vaccine in India’s immunisation programme would be a significant step toward reducing the cervical cancer burden. However, affordability, awareness, and systemic challenges must be addressed to achieve this goal.


March 2025
MTWTFSS
 12
3456789
10111213141516
17181920212223
24252627282930
31 
Categories